Therapeutic targeting of differentiation state-dependent metabolic vulnerabilities in DIPG
N. Mbah, A. Myers, C. Chung, J. Thompson, H. Hong, P. Sajjakulnukit, Z. Nwosu, M. Shan, S. Sweha, D. Maydan, B. Chen, L. Zhang, B. Magnuson, Z. Zui, D. Wahl, , C. A. Lyssiotis
This study identifies metabolic vulnerabilities in DIPG subtypes and shows that targeting these vulnerabilities with specific drugs can extend survival in preclinical models.
bioRxiv · Mar 1, 2022 · PreprintCancer Biology